Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

4

US Previously Marketed

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

30S ribosomal protein S12

4

DNA gyrase subunit B

3

DNA topoisomerase II

3

HSP90

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

7

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1956

3

1975

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cystic fibrosis

4

External infections of the eye

4

Bovine subclinical mastitis caused by Staphylococcus aureus and Streptococcus agalactiae

3

Breast cancer

3

Non-small cell lung cancer

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

7

Primary

7

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

4

CNS Non-penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Stark, W.M.|Hoehn, M.M.|Knox, N.G.

4

Pfizer|Upjohn

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

Mixture

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

FDA UNII

7

NCI_THESAURUS

6

PUBCHEM

6

ChEMBL

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

AMINOGLYCOSIDE ANTIBACTERIALS

1

ANTIINFECTIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antibiotics

1

Other aminoglycosides

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

TOBRAMYCIN

VZ8RRZ51VK

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1975

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

30S ribosomal protein S12

Conditions:

External infections of the eye

Cystic fibrosis

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary...

tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

NOVOBIOCIN

17EC19951N

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1956

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA gyrase subunit B

Conditions:

Non-small cell lung cancer

Bovine subclinical mastitis caused by Staphylococcus aureus and Streptococcus agalactiae

Staphylococcal Infections

Novobiocin (also known as streptonivicin) is an aminocoumarin antibiotic, active against Staphylococcus epidermidis. Novobiocin and other aminocoumarin antibiotics act as a potent competitive inhibitor of DNA gyrase B. The oral form of the drug was w...

ithdrawn from the market in 1999 due to safety or effectiveness reasons. Later it was discovered that novobiocin inhibited Hsp90 and topoisomerase II, and novobiocin was investigated in clinical trials against metastatic breast cancer and non-small cell lung cancer. Topical form of novobiocin was investigated in combination with nalidixic acid for treatment of psoriasis.

TOBRAMYCIN HYDROCHLORIDE

01IX3OU168

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1975

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

30S ribosomal protein S12

Conditions:

External infections of the eye

Cystic fibrosis

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary...

tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

TOBRAMYCIN SULFATE

HJT0RXD7JK

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1975

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

30S ribosomal protein S12

Conditions:

External infections of the eye

Cystic fibrosis

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary...

tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

NOVOBIOCIN SODIUM

Q9S9NQ5YIY

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1956

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA gyrase subunit B

Conditions:

Non-small cell lung cancer

Bovine subclinical mastitis caused by Staphylococcus aureus and Streptococcus agalactiae

Staphylococcal Infections

Novobiocin (also known as streptonivicin) is an aminocoumarin antibiotic, active against Staphylococcus epidermidis. Novobiocin and other aminocoumarin antibiotics act as a potent competitive inhibitor of DNA gyrase B. The oral form of the drug was w...

ithdrawn from the market in 1999 due to safety or effectiveness reasons. Later it was discovered that novobiocin inhibited Hsp90 and topoisomerase II, and novobiocin was investigated in clinical trials against metastatic breast cancer and non-small cell lung cancer. Topical form of novobiocin was investigated in combination with nalidixic acid for treatment of psoriasis.

NOVOBIOCIN CALCIUM

RHW5BU180N

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1956

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA gyrase subunit B

Conditions:

Non-small cell lung cancer

Bovine subclinical mastitis caused by Staphylococcus aureus and Streptococcus agalactiae

Staphylococcal Infections

Novobiocin (also known as streptonivicin) is an aminocoumarin antibiotic, active against Staphylococcus epidermidis. Novobiocin and other aminocoumarin antibiotics act as a potent competitive inhibitor of DNA gyrase B. The oral form of the drug was w...

ithdrawn from the market in 1999 due to safety or effectiveness reasons. Later it was discovered that novobiocin inhibited Hsp90 and topoisomerase II, and novobiocin was investigated in clinical trials against metastatic breast cancer and non-small cell lung cancer. Topical form of novobiocin was investigated in combination with nalidixic acid for treatment of psoriasis.

Nebramycin

NQJ13I4Z9U

Status:

US Approved Rx (2019)

First approved in 1975

Class:

MIXTURE

Targets:

30S ribosomal protein S12

Conditions:

External infections of the eye

Cystic fibrosis

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary...

tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1